PARIS--(BUSINESS WIRE)--LimFlow SA, developer of endovascular technology transforming the treatment of critical limb ischemia (CLI), has named Daniel Rose as chief executive officer (CEO), effective as of August 29. Former CEO and co-founder Timothy Lenihan has transitioned to the chief technology officer role to focus on continued enhancement of the company’s novel technology and maintains a role on the company’s board of directors.
Most recently, Mr. Rose served as vice president and general manager, Europe for Direct Flow Medical, an innovative developer of transcatheter heart valve technology. Prior to that, he served as the company’s vice president of sales and marketing, where he developed and led the execution of the global commercial strategy, ultimately establishing the company as a key competitor in the transcatheter aortic valve implantation (TAVI) market. Before that, he was vice president of commercial operations for Sequana Medical AG, driving commercial operations for the company’s proprietary implantable pump systems, playing a key role in its successful CHF 23.7 million Series B fundraising effort and serving on the company’s board of directors. Earlier, he held several leadership roles with Medtronic in Europe, including marketing director for the EMEA Coronary and Peripheral Vascular business and business manager for the Vascular division in the Nordics. Mr. Rose holds a dual-major BA, an MA and an MBA from the University of Virginia and its Darden Graduate School of Business.
“Dan has strong experience in leading medical device businesses and commercializing groundbreaking cardiovascular technologies in Europe and beyond,” said Mr. Lenihan. “His experience will be invaluable as we realize our mission to make LimFlow a leading innovator that enables physicians to change the lives of patients living with CLI.”
“LimFlow is transforming the treatment of patients facing the loss of a limb due to critical limb ischemia and chronic wounds, a growing clinical need in the face of the diabetes and vascular disease epidemics,” said Mr. Rose. “I am impressed with their innovative approach to solving this problem and the promising clinical results to date, and I look forward to leading the team to make this the standard of care for treating ‘no option’ CLI.”
CLI is the most severe form of peripheral artery disease (PAD), and is often caused by diabetes, obesity, age, high cholesterol, high blood pressure, and other factors, many of which are growing health problems. Patients with CLI experience profound, chronic pain, and often develop festering wounds or infections that lead to amputation of a foot or toes, dramatically limiting their mobility and quality of life. CLI has an incidence of 50 to 100 per 100,000 annually, and is associated with mortality rates as high as 20 percent six months after onset.1 Approximately 150,000 ischemic amputations occur in the United States each year, 2 and the total lifetime costs associated with lower extremity amputation total more than $95 billion in the US.3
The LimFlow System is a purely percutaneous approach to re-establishing lower limb perfusion in patients where traditional revascularization options are not feasible, with the goal of helping heal chronic wounds and enabling patients to avoid major amputation. The system employs two ultrasound-guided catheters, one venous and one arterial, to install several nitinol covered stents, creating an arterio-venous fistula and channeling blood supply to the ischemic foot.
First-in-Man and CE Mark clinical studies have been completed for the LimFlow System. The company has also submitted an application to obtain the CE Mark.
About LimFlow SA
LimFlow is a private, venture-backed medical device company transforming the treatment of Critical Limb Ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease, and an aging population. For more information, visit http://www.limflow.com/home/.
The LimFlow System is an investigational device, limited by applicable law to investigational use and is not available for sale.
- Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007 Jan;45 Suppl S:S5-67.
- Hirsch A, Duval S. The global pandemic of peripheral artery disease. Lancet. 2013 October 19;382(9901):1312-1314.
- Palli SR, Gunnarsson C, Kotlarz H, Martinsen BJ, Zhao R, Rizzo JA. Impact of a limb salvage program on the economic burden of amputation in the United States. ISPOR 21st Annual International Meeting, May 21-25, 2016; Washington, DC.